$CVSI
CV Sciences, Inc. Stock $cvsi

$cvsi Overview Financials Valuation SEC Filings Company Website

2023 Q2 Form 10-Q Financial Statement

#000151096423000024 Filed on May 15, 2023

Income Statement

Concept	2023 Q2	2023 Q1	2022 Q4
Revenue	$3.966M	$4.148M	$3.869M
YoY Change	-4.16%	-6.72%	-22.14%
Cost Of Revenue	$2.248M	$2.366M	$2.307M
YoY Change	-21.62%	-28.11%	-31.32%
Gross Profit	$1.718M	$1.782M	$1.562M
YoY Change	35.28%	54.15%	-2.98%
Gross Profit Margin	43.32%	42.96%	40.37%
Selling, General & Admin	$2.758M	$2.156M	$3.647M
YoY Change	-20.82%	-15.45%	-63.85%
% of Gross Profit	160.54%	120.99%	233.48%
Research & Development	$36.00K	$35.00K	$40.00K
YoY Change	-64.71%	-71.07%	-89.01%
% of Gross Profit	2.1%	1.96%	2.56%
Depreciation & Amortization	$59.00K	$59.00K	$69.00K
YoY Change	-82.8%	-88.59%	-83.05%
% of Gross Profit	3.43%	3.31%	4.42%
Operating Expenses	$2.794M	$2.191M	$3.687M
YoY Change	-22.06%	-17.97%	-64.73%
Operating Profit	-$1.076M	$5.762M	-$2.125M
YoY Change	-53.52%	-480.33%	-75.97%
Interest Expense	-$209.0K	-$56.00K	-$237.0K
YoY Change	-37.8%	-92.02%	111.61%
% of Operating Profit		-0.97%
Other Income/Expense, Net	-$209.0K	-$56.00K
YoY Change	-37.8%
Pretax Income	-$1.285M	$5.706M	-$2.362M
YoY Change	-51.53%	-357.37%	-73.62%
Income Tax	$3.000K	$0.00	-$49.00K
% Of Pretax Income		0.0%
Net Earnings	-$1.288M	$5.706M	-$2.313M
YoY Change	-51.45%	-357.37%	-73.89%
Net Earnings / Revenue	-32.48%	137.56%	-59.78%
Basic Earnings Per Share	-$0.01	$0.04
Diluted Earnings Per Share	-$0.01	$0.04	-$0.02
COMMON SHARES
Basic Shares Outstanding	152.1M shares	152.1M shares	150.1M shares
Diluted Shares Outstanding	152.6M shares	152.1M shares

Balance Sheet

Concept	2023 Q2	2023 Q1	2022 Q4
SHORT-TERM ASSETS
Cash & Short-Term Investments	$1.690M	$714.0K	$611.0K
YoY Change	51.71%	-70.73%	-55.56%
Cash & Equivalents	$1.690M	$714.0K	$611.0K
Short-Term Investments
Other Short-Term Assets	$411.0K	$2.103M	$3.190M
YoY Change	-87.22%	-39.01%	48.65%
Inventory	$5.836M	$6.526M	$6.563M
Prepaid Expenses			$3.190M
Receivables	$611.0K	$657.0K	$766.0K
Other Receivables	$0.00	$0.00	$0.00
Total Short-Term Assets	$8.548M	$10.00M	$11.13M
YoY Change	-32.37%	-33.57%	-21.54%
LONG-TERM ASSETS
Property, Plant & Equipment	$457.0K	$516.0K	$575.0K
YoY Change	-34.53%	-53.13%	-66.51%
Goodwill			$0.00
YoY Change
Intangibles	$251.0K	$251.0K	$251.0K
YoY Change	-83.1%	-83.1%	-83.1%
Long-Term Investments
YoY Change
Other Assets	$401.0K	$452.0K	$505.0K
YoY Change	-34.26%	-27.8%	-25.52%
Total Long-Term Assets	$1.331M	$1.468M	$1.606M
YoY Change	-57.33%	-54.3%	-58.61%
TOTAL ASSETS
Total Short-Term Assets	$8.548M	$10.00M	$11.13M
Total Long-Term Assets	$1.331M	$1.468M	$1.606M
Total Assets	$9.879M	$11.47M	$12.74M
YoY Change	-37.31%	-37.22%	-29.5%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.161M	$2.441M	$2.284M
YoY Change	-12.62%	-9.76%	-12.96%
Accrued Expenses	$3.537M	$3.241M	$9.690M
YoY Change	-64.38%	-68.46%	-11.22%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00	$0.00	$0.00
YoY Change	-100.0%	-100.0%	-100.0%
Long-Term Debt Due	$28.00K	$451.0K	$1.223M
YoY Change	-68.54%	153.37%	294.52%
Total Short-Term Liabilities	$5.849M	$6.253M	$13.31M
YoY Change	-56.85%	-55.95%	-7.93%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$125.0K	$157.0K	$188.0K
YoY Change	-49.8%
Total Long-Term Liabilities	$125.0K	$157.0K	$188.0K
YoY Change	-49.8%
TOTAL LIABILITIES
Total Short-Term Liabilities	$5.849M	$6.253M	$13.31M
Total Long-Term Liabilities	$125.0K	$157.0K	$188.0K
Total Liabilities	$5.985M	$6.421M	$13.51M
YoY Change	-56.84%	-54.96%	-6.95%
SHAREHOLDERS EQUITY
Retained Earnings	-$83.30M	-$82.00M	-$87.70M
YoY Change	-1.19%	0.37%	10.35%
Common Stock	$15.00K	$15.00K	$15.00K
YoY Change	7.14%	25.0%	36.36%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$3.894M	$5.047M	-$777.0K
YoY Change
Total Liabilities & Shareholders Equity	$9.879M	$11.47M	$12.74M
YoY Change	-37.31%	-37.22%	-29.5%

Cashflow Statement

Concept	2023 Q2	2023 Q1	2022 Q4
OPERATING ACTIVITIES
Net Income	-$1.288M	$5.706M	-$2.313M
YoY Change	-51.45%	-357.37%	-73.89%
Depreciation, Depletion And Amortization	$59.00K	$59.00K	$69.00K
YoY Change	-82.8%	-88.59%	-83.05%
Cash From Operating Activities	$1.411M	$975.0K	$210.0K
YoY Change	-220.7%	-343.75%	-118.04%
INVESTING ACTIVITIES
Capital Expenditures			$0.00
YoY Change
Acquisitions
YoY Change
Other Investing Activities
YoY Change
Cash From Investing Activities			$0.00
YoY Change
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	-435.0K	-$872.0K	-738.0K
YoY Change	178.85%	-160.43%	-183.96%
NET CHANGE
Cash From Operating Activities	1.411M	$975.0K	210.0K
Cash From Investing Activities			0.000
Cash From Financing Activities	-435.0K	-$872.0K	-738.0K
Net Change In Cash	976.0K	$103.0K	-528.0K
YoY Change	-173.66%	-90.32%	85.26%
FREE CASH FLOW
Cash From Operating Activities	$1.411M	$975.0K	$210.0K
Capital Expenditures			$0.00
Free Cash Flow			$210.0K
YoY Change			-118.04%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2023Q1	dei	Entity Central Index Key EntityCentralIndexKey	0001510964
CY2023Q1	dei	Amendment Flag AmendmentFlag	false
CY2023Q1	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2023Q1	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	Q1
CY2023Q1	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2023
CY2023Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2022Q1	us-gaap	Type Of Revenue Extensible List TypeOfRevenueExtensibleList	http://fasb.org/us-gaap/2022#ProductMember
CY2023Q1	dei	Document Type DocumentType	10-Q
CY2023Q1	dei	Document Quarterly Report DocumentQuarterlyReport	true
CY2023Q1	dei	Document Period End Date DocumentPeriodEndDate	2023-03-31
CY2023Q1	dei	Document Transition Report DocumentTransitionReport	false
CY2023Q1	dei	Entity File Number EntityFileNumber	000-54677
CY2023Q1	dei	Entity Registrant Name EntityRegistrantName	CV Sciences, Inc.
CY2023Q1	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	DE
CY2023Q1	dei	Entity Tax Identification Number EntityTaxIdentificationNumber	80-0944970
CY2023Q1	dei	Entity Address Address Line1 EntityAddressAddressLine1	9530 Padgett Street, Suite 107
CY2023Q1	dei	Entity Address City Or Town EntityAddressCityOrTown	San Diego
CY2023Q1	dei	Entity Address State Or Province EntityAddressStateOrProvince	CA
CY2023Q1	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	92126
CY2023Q1	dei	City Area Code CityAreaCode	866
CY2023Q1	dei	Local Phone Number LocalPhoneNumber	290-2157
CY2023Q1	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2023Q1	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2023Q1	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2023Q1	dei	Entity Small Business EntitySmallBusiness	true
CY2023Q1	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	false
CY2023Q1	dei	Entity Shell Company EntityShellCompany	false
CY2023Q2	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	152104789	shares
CY2023Q1	us-gaap	Cash Cash	714000	usd
CY2022Q4	us-gaap	Cash Cash	611000	usd
CY2023Q1	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	657000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	766000	usd
CY2023Q1	us-gaap	Inventory Net InventoryNet	6526000	usd
CY2022Q4	us-gaap	Inventory Net InventoryNet	6563000	usd
CY2023Q1	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	2103000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3190000	usd
CY2023Q1	us-gaap	Assets Current AssetsCurrent	10000000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	11130000	usd
CY2023Q1	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	516000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	575000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	249000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	275000	usd
CY2023Q1	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	251000	usd
CY2022Q4	us-gaap	Intangible Assets Net Excluding Goodwill IntangibleAssetsNetExcludingGoodwill	251000	usd
CY2023Q1	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	452000	usd
CY2022Q4	us-gaap	Other Assets Noncurrent OtherAssetsNoncurrent	505000	usd
CY2023Q1	us-gaap	Assets Assets	11468000	usd
CY2022Q4	us-gaap	Assets Assets	12736000	usd
CY2023Q1	us-gaap	Accounts Payable Current AccountsPayableCurrent	2441000	usd
CY2022Q4	us-gaap	Accounts Payable Current AccountsPayableCurrent	2284000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3241000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9690000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	120000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	117000	usd
CY2023Q1	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	451000	usd
CY2022Q4	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q4	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	1223000	usd
CY2023Q1	us-gaap	Liabilities Current LiabilitiesCurrent	6253000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	13314000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	157000	usd
CY2022Q4	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	188000	usd
CY2023Q1	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	11000	usd
CY2022Q4	us-gaap	Deferred Income Tax Liabilities Net DeferredIncomeTaxLiabilitiesNet	11000	usd
CY2023Q1	us-gaap	Liabilities Liabilities	6421000	usd
CY2022Q4	us-gaap	Liabilities Liabilities	13513000	usd
CY2023Q1	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2022Q4	us-gaap	Commitments And Contingencies CommitmentsAndContingencies		usd
CY2023Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	10000000	shares
CY2023Q1	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	87015000	usd
CY2023Q1	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Issued PreferredStockSharesIssued	1000	shares
CY2022Q4	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Shares Outstanding PreferredStockSharesOutstanding	0	shares
CY2023Q1	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2022Q4	us-gaap	Preferred Stock Value PreferredStockValue	0	usd
CY2023Q1	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.0001
CY2023Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2023Q1	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	152104000	shares
CY2023Q1	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	152104000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	152104000	shares
CY2022Q4	us-gaap	Common Stock Shares Issued CommonStockSharesIssued	152104000	shares
CY2023Q1	us-gaap	Common Stock Value CommonStockValue	15000	usd
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	86897000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-81983000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-87689000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5047000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-777000	usd
CY2023Q1	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	11468000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	12736000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4148000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4447000	usd
CY2023Q1	us-gaap	Cost Of Revenue CostOfRevenue	2366000	usd
CY2022Q1	us-gaap	Cost Of Revenue CostOfRevenue	3291000	usd
CY2023Q1	us-gaap	Gross Profit GrossProfit	1782000	usd
CY2022Q1	us-gaap	Gross Profit GrossProfit	1156000	usd
CY2023Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	35000	usd
CY2022Q1	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	121000	usd
CY2023Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2156000	usd
CY2022Q1	us-gaap	Selling General And Administrative Expense SellingGeneralAndAdministrativeExpense	2550000	usd
CY2023Q1	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	-6171000	usd
CY2022Q1	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	0	usd
CY2023Q1	cvsi	Operating Costs And Expenses Net OperatingCostsAndExpensesNet	-3980000	usd
CY2022Q1	cvsi	Operating Costs And Expenses Net OperatingCostsAndExpensesNet	2671000	usd
CY2023Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	5762000	usd
CY2022Q1	us-gaap	Operating Income Loss OperatingIncomeLoss	-1515000	usd
CY2023Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-56000	usd
CY2022Q1	us-gaap	Interest Income Expense Net InterestIncomeExpenseNet	-702000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	5706000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2217000	usd
CY2023Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	152104000	shares
CY2023Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	152104000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	116834000	shares
CY2022Q1	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	116834000	shares
CY2023Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	0.04
CY2022Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-1096000	usd
CY2023Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	0.04
CY2022Q1	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.02
CY2022Q1	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.02
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	-777000	usd
CY2023Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	118000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	5706000	usd
CY2023Q1	us-gaap	Stockholders Equity StockholdersEquity	5047000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	3543000	usd
CY2022Q1	cvsi	Stock Issued During Period Value Equity Commitment StockIssuedDuringPeriodValueEquityCommitment	554000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Conversion Of Convertible Securities StockIssuedDuringPeriodValueConversionOfConvertibleSecurities	1229000	usd
CY2022Q1	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	384000	usd
CY2022Q1	us-gaap	Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue	516000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2217000	usd
CY2022Q1	us-gaap	Stockholders Equity StockholdersEquity	4009000	usd
CY2023Q1	us-gaap	Net Income Loss NetIncomeLoss	5706000	usd
CY2022Q1	us-gaap	Net Income Loss NetIncomeLoss	-2217000	usd
CY2023Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	59000	usd
CY2022Q1	us-gaap	Depreciation Depletion And Amortization DepreciationDepletionAndAmortization	517000	usd
CY2023Q1	us-gaap	Share Based Compensation ShareBasedCompensation	118000	usd
CY2022Q1	us-gaap	Share Based Compensation ShareBasedCompensation	516000	usd
CY2023Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	0	usd
CY2022Q1	us-gaap	Gain Loss On Sale Of Property Plant Equipment GainLossOnSaleOfPropertyPlantEquipment	-99000	usd
CY2023Q1	cvsi	Debt Discount And Interest Expense DebtDiscountAndInterestExpense	100000	usd
CY2022Q1	cvsi	Debt Discount And Interest Expense DebtDiscountAndInterestExpense	699000	usd
CY2023Q1	cvsi	Employee Retention Credit Benefit EmployeeRetentionCreditBenefit	0	usd
CY2022Q1	cvsi	Employee Retention Credit Benefit EmployeeRetentionCreditBenefit	1993000	usd
CY2023Q1	cvsi	Noncash Lease Expense NoncashLeaseExpense	26000	usd
CY2022Q1	cvsi	Noncash Lease Expense NoncashLeaseExpense	0	usd
CY2023Q1	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	-6171000	usd
CY2022Q1	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	0	usd
CY2023Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	59000	usd
CY2022Q1	us-gaap	Other Operating Activities Cash Flow Statement OtherOperatingActivitiesCashFlowStatement	98000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Receivable IncreaseDecreaseInAccountsReceivable	-102000	usd
CY2023Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-37000	usd
CY2022Q1	us-gaap	Increase Decrease In Inventories IncreaseDecreaseInInventories	-387000	usd
CY2023Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-1087000	usd
CY2022Q1	us-gaap	Increase Decrease In Prepaid Deferred Expense And Other Assets IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets	-690000	usd
CY2023Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-148000	usd
CY2022Q1	us-gaap	Increase Decrease In Accounts Payable And Accrued Liabilities IncreaseDecreaseInAccountsPayableAndAccruedLiabilities	-271000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	975000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-379000	usd
CY2023Q1	cvsi	Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts	0	usd
CY2022Q1	cvsi	Proceeds From Issuance Of Preferred Stock And Common Stock Warrants Net Of Issuance Costs ProceedsFromIssuanceOfPreferredStockAndCommonStockWarrantsNetOfIssuanceCosts	605000	usd
CY2023Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	0	usd
CY2022Q1	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	970000	usd
CY2023Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	764000	usd
CY2022Q1	us-gaap	Repayments Of Notes Payable RepaymentsOfNotesPayable	0	usd
CY2023Q1	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	108000	usd
CY2022Q1	us-gaap	Repayments Of Unsecured Debt RepaymentsOfUnsecuredDebt	132000	usd
CY2023Q1	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1952000	usd
CY2023Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-872000	usd
CY2022Q1	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1443000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	103000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	1064000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	611000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	1375000	usd
CY2023Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	714000	usd
CY2022Q1	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2439000	usd
CY2023Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	usd
CY2022Q1	us-gaap	Income Taxes Paid Net IncomeTaxesPaidNet	3000	usd
CY2023Q1	cvsi	Increase Decrease In Convertible Note IncreaseDecreaseInConvertibleNote	0	usd
CY2022Q1	cvsi	Increase Decrease In Convertible Note IncreaseDecreaseInConvertibleNote	-675000	usd
CY2023Q1	cvsi	Services Paid With Common Stock ServicesPaidWithCommonStock	0	usd
CY2022Q1	cvsi	Services Paid With Common Stock ServicesPaidWithCommonStock	384000	usd
CY2023Q1	cvsi	Issuance Cost In Accounts Payable And Accrued Expenses IssuanceCostInAccountsPayableAndAccruedExpenses	0	usd
CY2022Q1	cvsi	Issuance Cost In Accounts Payable And Accrued Expenses IssuanceCostInAccountsPayableAndAccruedExpenses	-68000	usd
CY2023Q1	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	usd
CY2022Q4	us-gaap	Inventory Finished Goods InventoryFinishedGoods	1980000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-1900000	usd
CY2023Q1	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-82000000	usd
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	700000	usd
CY2023Q1	cvsi	Cares Act Tax Credit Received Under Relief Provision CARESActTaxCreditReceivedUnderReliefProvision	2000000	usd
CY2022Q3	cvsi	Cares Act Tax Credit Received Under Relief Provision CARESActTaxCreditReceivedUnderReliefProvision	500000	usd
CY2023Q1	cvsi	Cares Act Total Tax Credit Received Under Relief Provision CARESActTotalTaxCreditReceivedUnderReliefProvision	2500000	usd
CY2023Q1	cvsi	Cares Act Proceeds Received Under Relief Provision CARESActProceedsReceivedUnderReliefProvision	1100000	usd
CY2023Q1	us-gaap	Use Of Estimates UseOfEstimates	<span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-style:italic;font-weight:700;line-height:120%">Use of Estimates</span><span style="color:#000000;font-family:'Times New Roman',sans-serif;font-size:10pt;font-weight:400;line-height:120%"> - The preparation of the condensed financial statements in conformity with U.S. GAAP requires management to make judgments, estimates and assumptions that affect the reported amounts in the condensed financial statements and accompanying notes. Actual results may differ from these estimates. Significant estimates include the valuation of intangible assets, inputs for valuing equity awards, valuation of inventory and assumptions related to revenue recognition.</span>
CY2022Q4	us-gaap	Assets Fair Value Disclosure AssetsFairValueDisclosure	0	usd
CY2023Q1	us-gaap	Inventory Gross InventoryGross	6526000	usd
CY2023Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4148000	usd
CY2022Q1	us-gaap	Revenue From Contract With Customer Excluding Assessed Tax RevenueFromContractWithCustomerExcludingAssessedTax	4447000	usd
CY2023Q1	us-gaap	Inventory Raw Materials InventoryRawMaterials	3424000	usd
CY2022Q4	us-gaap	Inventory Raw Materials InventoryRawMaterials	3563000	usd
CY2023Q1	us-gaap	Inventory Work In Process InventoryWorkInProcess	1150000	usd
CY2022Q4	us-gaap	Inventory Work In Process InventoryWorkInProcess	1020000	usd
CY2022Q4	us-gaap	Inventory Gross InventoryGross	6563000	usd
CY2022Q1	us-gaap	Inventory Write Down InventoryWriteDown	100000	usd
CY2023Q1	us-gaap	Inventory Write Down InventoryWriteDown	0	usd
CY2023Q1	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	522000	usd
CY2022Q4	us-gaap	Accrued Payroll Taxes Current AccruedPayrollTaxesCurrent	6694000	usd
CY2023Q1	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1350000	usd
CY2022Q4	us-gaap	Accrued Salaries Current AccruedSalariesCurrent	1447000	usd
CY2023Q1	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1369000	usd
CY2022Q4	us-gaap	Other Accrued Liabilities Current OtherAccruedLiabilitiesCurrent	1549000	usd
CY2023Q1	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	3241000	usd
CY2022Q4	us-gaap	Accrued Liabilities Current AccruedLiabilitiesCurrent	9690000	usd
CY2022Q2	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	300000	usd
CY2022Q2	us-gaap	Operating Lease Liability OperatingLeaseLiability	400000	usd
CY2023Q1	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	200000	usd
CY2023Q1	us-gaap	Operating Lease Cost OperatingLeaseCost	0	usd
CY2023Q1	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P26M
CY2023Q1	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.070
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Remainder Of Fiscal Year LesseeOperatingLeaseLiabilityPaymentsRemainderOfFiscalYear	102000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	139000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	59000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Payments Due LesseeOperatingLeaseLiabilityPaymentsDue	300000	usd
CY2023Q1	us-gaap	Lessee Operating Lease Liability Undiscounted Excess Amount LesseeOperatingLeaseLiabilityUndiscountedExcessAmount	23000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	277000	usd
CY2023Q1	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	120000	usd
CY2023Q1	us-gaap	Operating Lease Liability Noncurrent OperatingLeaseLiabilityNoncurrent	157000	usd
CY2023Q1	us-gaap	Operating Lease Liability OperatingLeaseLiability	277000	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Amount1 DebtConversionConvertedInstrumentAmount1	151772	usd
CY2022Q2	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	3751971	shares
CY2022Q2	us-gaap	Debt Instrument Convertible Conversion Price1 DebtInstrumentConvertibleConversionPrice1	0.04
CY2022Q1	us-gaap	Debt Conversion Converted Instrument Shares Issued1 DebtConversionConvertedInstrumentSharesIssued1	6804281	shares
CY2022Q1	us-gaap	Interest Expense Debt InterestExpenseDebt	600000	usd
CY2022Q3	us-gaap	Gains Losses On Extinguishment Of Debt GainsLossesOnExtinguishmentOfDebt	127000	usd
CY2022Q3	us-gaap	Write Off Of Deferred Debt Issuance Cost WriteOffOfDeferredDebtIssuanceCost	50000	usd
CY2023Q1	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	451000	usd
CY2022Q4	cvsi	Long Term Debt Excluding Convertible Debt Current Maturities LongTermDebtExcludingConvertibleDebtCurrentMaturities	1223000	usd
CY2023Q1	cvsi	Caresact Proceeds To Be Remitted To Lender Minimum CARESACTProceedsToBeRemittedToLenderMinimum	1000000	usd
CY2022Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	200000000	shares
CY2022Q2	us-gaap	Capital Units Authorized CapitalUnitsAuthorized	800000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2022Q2	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2022Q1	us-gaap	Class Of Warrant Or Right Number Of Securities Called By Warrants Or Rights ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Par Or Stated Value Per Share PreferredStockParOrStatedValuePerShare	0.0001
CY2022Q1	us-gaap	Proceeds From Issuance Of Preferred Stock And Preference Stock ProceedsFromIssuanceOfPreferredStockAndPreferenceStock	700000	usd
CY2022Q1	us-gaap	Payments Of Stock Issuance Costs PaymentsOfStockIssuanceCosts	600000	usd
CY2022Q1	cvsi	Sale Of Stock Deduction From Proceeds Related To Agents Fees And Other Offering Expenses SaleOfStockDeductionFromProceedsRelatedToAgentsFeesAndOtherOfferingExpenses	100000	usd
CY2022Q1	cvsi	Preferred Stock Par Or Stated Value Per Share Subjected To Conversion PreferredStockParOrStatedValuePerShareSubjectedToConversion	1000
CY2022Q1	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	10000000	shares
CY2022Q1	us-gaap	Preferred Stock Convertible Conversion Price PreferredStockConvertibleConversionPrice	0.07
CY2022Q1	cvsi	Class Of Warrants Or Rights Fair Value Recorded As Additional Offering Cost ClassOfWarrantsOrRightsFairValueRecordedAsAdditionalOfferingCost	100000	usd
CY2022Q1	us-gaap	Preferred Stock Convertible Shares Issuable PreferredStockConvertibleSharesIssuable	10000000	shares
CY2022Q1	cvsi	Preferred Stock Number Of Votes Per Share PreferredStockNumberOfVotesPerShare	170000	vote
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	200000000	shares
CY2022Q1	us-gaap	Preferred Stock Shares Authorized PreferredStockSharesAuthorized	800000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	190000000	shares
CY2022Q1	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	790000000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	0.04
CY2023Q1	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10750000	shares
CY2022Q4	us-gaap	Class Of Warrant Or Right Outstanding ClassOfWarrantOrRightOutstanding	10750000	shares
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized	300000	usd
CY2023Q1	us-gaap	Employee Service Share Based Compensation Nonvested Awards Total Compensation Cost Not Yet Recognized Period For Recognition1 EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1	P2Y9M18D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	19831000	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.46
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P3Y6M
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriod	7450000	shares
CY2023Q1	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	0	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod	2550000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.45
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber	24731000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.33
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term2 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2	P5Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	4000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableNumber	16318000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsExercisableWeightedAverageExercisePrice	0.48
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableWeightedAverageRemainingContractualTerm1	P2Y8M12D
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Exercisable Intrinsic Value1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1	0	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Outstanding Number ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber	24731000	shares
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	0.33
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageRemainingContractualTerm1	P5Y1M6D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Aggregate Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableAggregateIntrinsicValue	4000	usd
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedVolatilityRate	1.320
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Risk Free Interest Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsRiskFreeInterestRate	0.038
CY2023Q1	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P5Y9M7D
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0
CY2023Q1	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Weighted Average Grant Date Fair Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue	0.04
CY2023Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	42231000	shares
CY2022Q1	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	57414000	shares
CY2022Q2	cvsi	Loss Contingency Issuance Of Interim Awarding Related To Purchase Of Psl And Other Advance Payments LossContingencyIssuanceOfInterimAwardingRelatedToPurchaseOfPSLAndOtherAdvancePayments	300000	usd
CY2022Q2	cvsi	Termination Severance And Other Post Termination Compensation And Benefits Under His Employment Agreement TerminationSeveranceAndOtherPostTerminationCompensationAndBenefitsUnderHisEmploymentAgreement	600000	usd
CY2022Q4	us-gaap	Loss Contingency Accrual At Carrying Value LossContingencyAccrualAtCarryingValue	300000	usd
CY2023Q1	us-gaap	Loss Contingency Damages Awarded Value LossContingencyDamagesAwardedValue	17481	usd
CY2023Q1	cvsi	Net Operating Loss Tax Benefit Recognized NetOperatingLossTaxBenefitRecognized	0	usd
CY2022Q1	cvsi	Net Operating Loss Tax Benefit Recognized NetOperatingLossTaxBenefitRecognized	0	usd
CY2023Q1	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	-6200000	usd
CY2023Q1	cvsi	Payroll Tax Expense Reversal PayrollTaxExpenseReversal	-6200000	usd

Files In Submission

Name	View Source	Status
cvsi-20230331_cal.xml	Edgar Link	unprocessable
0001510964-23-000024-index-headers.html	Edgar Link	pending
0001510964-23-000024-index.html	Edgar Link	pending
0001510964-23-000024.txt	Edgar Link	pending
0001510964-23-000024-xbrl.zip	Edgar Link	pending
cvsi-20230331.htm	Edgar Link	pending
cvsi-20230331.xsd	Edgar Link	pending
cvsi-2023331xex311.htm	Edgar Link	pending
cvsi-2023331xex312.htm	Edgar Link	pending
cvsi-2023331xex321.htm	Edgar Link	pending
cvsi-2023331xex322.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
cvsi-20230331_def.xml	Edgar Link	unprocessable
cvsi-20230331_lab.xml	Edgar Link	unprocessable
cvsi-20230331_pre.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
cvsi-20230331_htm.xml	Edgar Link	completed
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$CVSI
CV Sciences, Inc. Stock $cvsi

2023 Q2 Form 10-Q Financial Statement

#000151096423000024 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVSI CV Sciences, Inc. Stock $cvsi

2023 Q2 Form 10-Q Financial Statement

#000151096423000024 Filed on May 15, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$CVSI
CV Sciences, Inc. Stock $cvsi